PubMed COVID-19 Clinical Care

The continuous surprises that SARS-CoV-2 presents to the scientific community - Correspondence about the Paper Fusco G, Cardillo L, Levante M, Brandi S, Picazio G, Napoletano M, Martucciello A, Fiorito F, De Carlo E, De Martinis C. First serological ev...

Tuesday, January 30, 2024 - 4:00 AM

No abstract

Effectiveness of primary series, first, and second booster vaccination of monovalent mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections and severe diseases during the SARS-CoV-2 omicron BA.5 epidemic in Japan: vaccine effectiveness real-t...

Tuesday, January 30, 2024 - 4:00 AM

CONCLUSION: mRNA Booster vaccination provided moderate protection against symptomatic infections and high-level protection against severe diseases during the BA.5 epidemic in Japan.

The continuous surprises that SARS-CoV-2 presents to the scientific community - Correspondence about the Paper Fusco G, Cardillo L, Levante M, Brandi S, Picazio G, Napoletano M, Martucciello A, Fiorito F, De Carlo E, De Martinis C. First serological ev...

Tuesday, January 30, 2024 - 4:00 AM

No abstract

Effectiveness of primary series, first, and second booster vaccination of monovalent mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections and severe diseases during the SARS-CoV-2 omicron BA.5 epidemic in Japan: vaccine effectiveness real-t...

Tuesday, January 30, 2024 - 4:00 AM

CONCLUSION: mRNA Booster vaccination provided moderate protection against symptomatic infections and high-level protection against severe diseases during the BA.5 epidemic in Japan.

The continuous surprises that SARS-CoV-2 presents to the scientific community - Correspondence about the Paper Fusco G, Cardillo L, Levante M, Brandi S, Picazio G, Napoletano M, Martucciello A, Fiorito F, De Carlo E, De Martinis C. First serological ev...

Tuesday, January 30, 2024 - 4:00 AM

No abstract

Effectiveness of primary series, first, and second booster vaccination of monovalent mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections and severe diseases during the SARS-CoV-2 omicron BA.5 epidemic in Japan: vaccine effectiveness real-t...

Tuesday, January 30, 2024 - 4:00 AM

CONCLUSION: mRNA Booster vaccination provided moderate protection against symptomatic infections and high-level protection against severe diseases during the BA.5 epidemic in Japan.

The continuous surprises that SARS-CoV-2 presents to the scientific community - Correspondence about the Paper Fusco G, Cardillo L, Levante M, Brandi S, Picazio G, Napoletano M, Martucciello A, Fiorito F, De Carlo E, De Martinis C. First serological ev...

Tuesday, January 30, 2024 - 4:00 AM

No abstract

Effectiveness of primary series, first, and second booster vaccination of monovalent mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections and severe diseases during the SARS-CoV-2 omicron BA.5 epidemic in Japan: vaccine effectiveness real-t...

Tuesday, January 30, 2024 - 4:00 AM

CONCLUSION: mRNA Booster vaccination provided moderate protection against symptomatic infections and high-level protection against severe diseases during the BA.5 epidemic in Japan.

The continuous surprises that SARS-CoV-2 presents to the scientific community - Correspondence about the Paper Fusco G, Cardillo L, Levante M, Brandi S, Picazio G, Napoletano M, Martucciello A, Fiorito F, De Carlo E, De Martinis C. First serological ev...

Tuesday, January 30, 2024 - 4:00 AM

No abstract

Effectiveness of primary series, first, and second booster vaccination of monovalent mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections and severe diseases during the SARS-CoV-2 omicron BA.5 epidemic in Japan: vaccine effectiveness real-t...

Tuesday, January 30, 2024 - 4:00 AM

CONCLUSION: mRNA Booster vaccination provided moderate protection against symptomatic infections and high-level protection against severe diseases during the BA.5 epidemic in Japan.